April 30, 2021
BLOODPAC Data Commons for Liquid Biopsy Data
ASCO JCO Clinical Cancer Informatics
The Blood Profiling Atlas in Cancer (BLOODPAC) Data Commons (BPDC) is being developed and is operated by the public-private BLOODPAC Consortium to support the liquid biopsy community. It is an interoperable data commons with the ultimate aim of serving as a recognized source of valid scientific evidence for liquid biopsy assays for industry, academia, and standards and regulatory stakeholders.
April 2, 2020
The COVID-19 Testing We Need
The following framework was initially created by the BloodPAC Policy and Reimbursement Working Group to help provide a meaningful understanding of the challenges of rapidly and efficiently increasing COVID-19 testing of the entire US population. In this post, we provide an overview of the three types of COVID-19 testing, and the process required to accelerate the return to normal economic activity as soon, and safely, as possible.
April 2, 2020
We Don’t Need a COVID-19 Test. We Need 3.
The universal questions bearing down on everyone navigating the social distancing measures in response to the COVID-19 pandemic is: How long do we do this? When does it end? How does it end? Any date projections are mere guesses. The key to resuming normal economic, social and community activities is widespread testing designed to provide the full spectrum of data and information needed to inform a cohesive, responsible return to work and daily living. Without this full spectrum of understanding, society and U.S. businesses will invariably suffer from an extended, repeated cycle of “one step forward, two steps back” fostered by premature decisions, half-measures or overcorrections.
February 4, 2020
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases
Clinical Pharmacology and Therapeutics
BLOODPAC is a public–private consortium that develops standards and best practices, organizes and coordinates research studies through its members, and operates a data commons to support the liquid biopsy research community. Data from the studies it organizes are contributed to the BLOODPAC Data Commons. BLOODPAC developed recommendations for 11 preanalytical attributes called the Minimum Technical Data Elements (MTDEs) that are recommended for studies that it sponsors and for data contributed to the BLOODPAC Data Commons.
August - October 2019
The Veterans Precision Oncology Data Commons: Transforming VA data into a national resource for research in precision oncology
Science Direct: Seminars in Oncology
The Department of Veterans Affairs (VA) has a strong track record providing high-quality, evidence-based care to cancer patients. In order to accelerate discoveries that will further improve care for Veterans with cancer, the VA has partnered with the Center for Translational Data Science at the University of Chicago and the Open Commons Consortium to establish a data sharing platform, the Veterans Precision Oncology Data Commons (VPODC). The VPODC makes clinical, genomic, and imaging data from the VA available to the research community at large.
February 10, 2017
Collaborating to Compete: Blood Profiling Atlas in Cancer (BLOODPAC) Consortium
Clinical Pharmacology and Therapeutics
The cancer community understands the value of blood profiling measurements in assessing and monitoring cancer. We describe an effort among academic, government, biotechnology, diagnostic, and pharmaceutical companies called the Blood Profiling Atlas in Cancer (BLOODPAC) Project. BLOODPAC will aggregate, make freely available, and harmonize for further analyses, raw datasets, relevant associated clinical data (e.g., clinical diagnosis, treatment history, and outcomes), and sample preparation and handling protocols to accelerate the development of blood profiling assays.